About: Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements
Creator	Kulkarni, Sanjay Mutalik, Srinivas Nikam, Ajinkya Fernandes, Gasper Gopalan, Divya Mutalik, Sadhana Pandey, Abhjieet Prassl, Ruth Shreya, Ajjappla Biophysics, Ruth Nikam, Nitin Singh Padya, Bharath
Source	Elsevier; Medline; PMC
abstract	The present pandemic of SARS-CoV-2 has been a tough task for the whole world to deal with. With the absence of specific drugs or vaccines against SARS-CoV-2, the situation is very difficult to control. Apart from the absence of specific therapies, the lack of knowledge about potential therapeutic targets and individual perception is adding to the complications. The present review describes the novel SARS-CoV-2 structure, surface proteins, asymptomatic and symptomatic transmission in addition to the genotype and phenotype of SARS-CoV-2 along with genetic strains and similarity between SARS, MERS and SARS-CoV-2. Therapeutic strategies such as inhibition of the endocytic pathway and suppressing RNA polymerase activity by metal ions, which could be quite beneficial for controlling COVID-19, are outlined. The drug repurposing for SARS-CoV-2 is discussed in detail along with therapeutic classes such as antivirals, antibiotics, and amino quinolones and their probable role in suppressing SARS-CoV-2 with reference to case studies. The ongoing clinical trials both with respect to drug repurposing and vaccines are summarized along with a brief description. The recent advancements and future perspective of ongoing research for therapy and detection of SARS-CoV-2 are provided. The review, in brief, summarizes epidemiology, therapy and the current scenario for combating SARS-CoV-2.
has issue date	2020-06-01(xsd:dateTime)
bibo:doi	10.1016/j.lfs.2020.117883
bibo:pmid	32497632
has license	no-cc
sha1sum (hex)	04617a86a87b436dd59ee5be9f396e48304e5200
schema:url	https://doi.org/10.1016/j.lfs.2020.117883
resource representing a document's title	Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements
has PubMed Central identifier	PMC7263255
has PubMed identifier	32497632
schema:publication	Life Sci
resource representing a document's body	covid:04617a86a87b436dd59ee5be9f396e48304e5200#body_text
is schema:about of	named entity 'Therapeutic Targets' named entity 'C-reactive protein' named entity 'bat' named entity 'enzyme' named entity 'SARS-CoV-2' named entity 'Baricitinib' named entity 'transmembrane domain' named entity 'proteases' named entity 'influenza' named entity 'prodrug' named entity 'liver' named entity 'clinical study' named entity 'actinomycete' named entity 'genetic material' named entity 'Hubei' named entity 'China' named entity 'flavivirus' named entity 'pathogenicity' named entity 'host cell' named entity 'JAK1' named entity 'double-blind' named entity 'anti-bacterial' named entity 'respiratory viral infections' named entity 'plasma' named entity 'SARS-CoV' named entity 'immunosuppressant' named entity 'fever' named entity 'parasite' named entity 'spike protein' named entity 'Staphylococcal' named entity 'oral mucosa' named entity 'oral administration' named entity 'protein' named entity 'methylprednisolone' named entity 'COVID-19' named entity 'bronchial epithelial cells' named entity 'coronavirus' named entity 'cathepsin' named entity 'secretion' named entity 'peptidoglycan' named entity 'transcription' named entity 'chloroquine' named entity 'virus' named entity 'COVID-19' named entity 'recombination hotspots' named entity 'viral life cycle' named entity 'viral replication' named entity 'SARS-CoV-2' named entity 'ARDS' named entity 'catalytic site' named entity 'TMPRSS2' named entity 'purine' named entity 'leukopenia' named entity 'non-human primate' named entity 'janus kinase' named entity 'intravenous' named entity 'clinical trials' named entity 'ferritin' named entity 'upper respiratory' named entity 'vaccines' named entity 'RT-PCR' named entity 'vaccines' named entity 'immune reaction' named entity 'RBD' named entity 'virucidal' named entity 'Phase-1' named entity 'receptor' named entity 'immune cell' named entity 'HIV protease inhibitors' named entity 'endocytosis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software